Sự phục hồi tế bào lympho bị suy giảm ở bệnh nhân mắc bệnh bạch cầu lympho mãn tính và lymphoma không Hodgkin thể thụ động được điều trị bằng bendamustine kết hợp với rituximab

Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:45–51 Czuczman MS, Weaver R, Alkuzweny B et al (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non Hodgkin treated with rituximab plus CHOP chemotherapy: 9 year follow up. J Clin Oncol 22:4711–4716 Cragg MS, Glennie MJ (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738–2743 Mosser E, Brunker P, Moser S et al (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B cell cytotoxicity. Blood 115:4393–4402 Braza MS, Klein B, Fiol G, Rossi JF (2011) γδ T cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica 96:400–407 Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Eng J Med 370:1101–1110 Bendandi M, Gocke CD, Kobrin CB et al (1999) Complete molecular remissions induced by patient specific vaccination plus granulocyte monocyte colony stimulating factor against lymphoma. Nat Med 5:1171.1177 Inogés S, Rodriguez-Calvillo M, Zabalegui N et al (2006) Clinical benefit associated with idiotype vaccination in patients with follicular lymphoma. J Natl Cancer Inst 98:1292–1301 Rituximab and autologous effector lymphocytes in non-Hodgkin follicular lymphoma in response to first line chemotherapy. Clinical Trials. Gov identifier NCT01329354 Flinn IW, van der Jagt R, Kahl BS et al (2014) Open label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment advanced indolent NHL or MCL: the BRIGHT study. Blood. doi:10.1182/Blood-2013-11-531327 Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus Rituximab versus CHOP plus Rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open label, multicentre randomised, phase 3 non inferiority trial. Lancet 6736:61763–2 Fischer K, Cramper P, Busch R, Böttcher S, Bahlo J, Schubert J et al (2012) Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukaemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukaemia Study Group. J Clin Oncol 30:3209–3216 Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hacker R, Kofahl-Krause D et al (2005) Bendamustine plus Rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and indolent non-Hodgkin’s lymphoma. J Clin Oncol 23:3383–3389 Georgiana G, Perez-Andres M, Barrena S, Rivas RA, Gonzalez M, Rabasa P et al (2013) Effects of Bendamustine plus Rituximab on the distribution of normal peripheral blood leucocyte populations in advanced stage chronic lymphocytic leukemia (CLL). Blood 122:5289 Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB et al (2013) Sever and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol 71:1183–1190 Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253 Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586 Cheson BD, Bennet JM, Grever M et al (2002) National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 100:2289–2290 Rawstron A, Villamor N, Ritgen M et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukemia. Leukemia 21:956–964 Rawal S, Chu F, Zhang M et al (2013) Cross talk between follicular Th cells and tumor cells in follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 190:6681–6693 García-Muñoz R, Llorente L (2014) Chronic lymphocytic leukemia (CLL): could immunological tolerance mechanisms be the origin of lymphoid neoplasms? Immunology. doi:10.1111/imm.12285 Witheside TL, Robinson B, June CH, Lotze MT (2013) Principles of tumor immunology. In Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyland CM (eds) Clinical Immunology. Principles and Practice. 4th edn. Elsevier Saunders 925-934 Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F et al (2009) Follicular lymphoma cells induce T cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114:4713–4720 Ai WZ, Novak AJ, Hou JZ, Zeizer R, Czerwinski D, Negrin RS, Levy R (2009) Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T regulatory cells. Int J Cancer 124:239–244 Yang ZZ, Novak AJ, Stenson MJ, Witzing TE, Ansell SM (2006) Intratumoral CD4 + CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639–3646 Yang ZZ, Novak AJ, Ziesmer SC, Witzing TE, Ansell SM (2006) Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res 66:1045–10152 Kiali S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A et al (2013) Follicular lymphoma cells induce changes in T cell gene expression and function: potential impact on survival and risk of transformation. J ClinOncol 31:2654–2661 Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427–2437 Ramsay AG, Clear AJ, Fatah R, Gribben JG (2012) Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 120:1412–1421 Weiss L, Melchardt T, Eagle A, Grabmer C, Greil R, Tinhofer I (2009) Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 27:e5–e6 D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G et al (2012) A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 87:628–631 Lad DP, Varma S, Varma N, Sachdeva MU, Bose P, Malhotra P (2013) Regulatory T cells in B cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 54:1012–1019 Sampalo A, Brieva JH (2002) Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/95L in tumoral damage and escape. Leuk Lymphoma 43:881–884 Hallek M (2013) Singalling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematol Am Soc Hematol Educ Program 2013:138–150 Hosoda T, Yokoyama A, Yoneda M, Yamamoto R, Ohashi K, Kagoo T et al (2013) Bendamustine can severely impair T cell immunity against cytomegalovirus. Leuk Lymphoma 54:1327–1328 García-Muñoz R, García DK, Roldan-Galiacho V, Merchante-Andreu M, Campeny-Najara A, Rabasa P (2014) Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine. Ann Hematol 93:699–702